NK cell therapy after surgery for pancreatic or bile duct cancer
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests whether adding natural killer (NK) cell therapy to standard chemotherapy after surgery can help prevent pancreatic or bile duct cancer from coming back. It is for patients who have had their tumor completely removed and are now ready for adjuvant chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had surgery for pancreatic or bile duct cancer within the past 12 weeks.
- Your cancer was stage II or III at the time of surgery, and the surgeon removed it completely (R0 or R1 margins).
- You are planning to receive standard chemotherapy (SLOG regimen) after surgery.
- You are generally healthy enough for daily activities (ECOG 0 or 1).
- Your blood counts, liver, and kidney function are within certain limits.
- You have had a past CMV infection (most adults have) and test negative for HIV and syphilis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new therapy using your own immune cells (NK cells) that are specially trained to find and attack cancer cells. It is for people with pancreatic cancer that has not responded to previous treatment.
This trial tests an experimental NK cell therapy (PANK-003) given along with standard chemotherapy after surgery for solid tumors. The goal is to see if adding these immune cells can help prevent the cancer from coming back.
This trial tests a new type of immune cell therapy called CAR-NK cells that target two proteins (MSLN and MUC1) often found on pancreatic cancer cells. It is for people whose cancer has spread or cannot be removed, and who have already tried at least one standard treatment.
This trial is testing a new type of immune cell therapy called PANK-003, given alongside standard chemotherapy after surgery for stage IIIA non-small cell lung cancer (NSCLC). It aims to see if this combination can help prevent the cancer from coming back.
This trial tests adding natural killer (NK) cell therapy to standard chemo and immunotherapy before surgery for stage IB to IIIA non-small cell lung cancer that can be removed. It aims to see if this combination helps shrink tumors and improve outcomes.
This trial tests a new treatment using immune cells (CAR-NK cells) to fight pancreatic cancer that has spread or come back. It may be an option if standard treatments have stopped working, were not tolerated, or were refused.
Hear when a new Cholangiocarcinoma Resectable trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.